Work

Supplementary Figure S8 from Optimization of a Novel 2 + 2 BCMA × CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy

Year: 2025

Type: supplementary-materials

Abstract: Illustration of dosing schedule and dose escalation for the phase I clinical trial (NCT04735575).

DOI: 10.1158/1535-7163.30255370

Authors: Danqing Wu, Lini Huang, Gaowa Naren, Rui Zhang, Shiyong Gong, Xuan Wu, Chengbin Wu

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4414747011

Cites:

Cited by:

Related to: